[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350124-105":59,"doc-detail-350124-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cell-drug-conjugates-a-novel-drug-delivery-system-for-cancer-therapy","Cell-drug conjugates: a novel drug delivery system for cancer therapy","","Cell-drug conjugates (CDCs) combine living cells with therapeutics to enable precise targeting by exploiting inherent cellular biology. By conjugating drugs onto cell surfaces, CDCs maintain cell viability and support collaborative therapy between drugs and the carrier cells. The approach can also enhance drug pharmacokinetics. This review details CDC construction as delivery systems, covering carrier cell types, coupling components, conjugation strategies, and highlights advantages and cancer applications, including clinical trial analysis, while addressing key challenges and future directions toward clinical translation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cell-drug-conjugates-a-novel-drug-delivery-system-for-cancer-therapy/350124/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cell-drug-conjugates-a-novel-drug-delivery-system-for-cancer-therapy/350124.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are cell-drug conjugates (CDCs) and how do they achieve targeting?","Question",{"text":112,"@type":113},"CDCs are a drug delivery platform that combines living cells with therapeutics. Drugs are conjugated onto cell surfaces so the system leverages cellular biology for more precise targeting while preserving cell viability.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What challenges limit biomimetic nano-drug delivery systems (BNDDS) in clinical translation?",{"text":117,"@type":113},"Because BNDDS are still nanoparticle-based, they face structural and interface-related issues such as weak membrane–core adhesion and rapid clearance. Tumor microenvironment heterogeneity and protein denaturation during preparation can further reduce in vivo effectiveness.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the “living carrier” strategy address limitations of other delivery systems?",{"text":121,"@type":113},"CDCs use live cells as delivery vehicles, avoiding certain structural bottlenecks of BNDDS. Therapeutics can be anchored to cell membranes via covalent/non-covalent methods or via genetic engineering, enabling functional integration and collaborative therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350124,1790460015,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Theranostics 2026, Vol. 16, Issue 10 5319  \nIvyspring  \nInternational Publisher  \nTheranostics  \n2026; 16(10): 5319-5347. doi: 10.7150/thno.127171  \nReview  \nCell-drug conjugates: a novel drug delivery system for cancer therapy  \nXiaoli Cheng1\\#, Mengyuan He1\\#, Yuanye Zeng2,5, Aixue Li2,5, Lianghao Yuan3, Yongwei Gu2,5, Haiqiang Jiang1􀀍, Jiyong Liu1,2,4,5􀀍  \n1. School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.  \n2. Department of Pharmacy, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.  \n3. College of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.  \n4. Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China.  \n5. State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, 210000, China.  \n\\# These authors contributed equally to this work.  \n􀀍 Corresponding authors: Jiyong Liu, Email: [liujiyong@fudan.edu.cn](liujiyong@fudan.edu.cn); Haiqiang Jiang, Email: [jhq12723@163.com](jhq12723@163.com).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.10.22; Accepted: 2026.02.09; Published: 2026.03.09  \nAbstract  \n\n| Cell-drug conjugates (CDCs) represent an advanced drug delivery platform that combines living cells with therapeutics, leveraging the biological properties of cells to achieve precise targeting. By conjugating drugs onto cell surfaces, CDCs preserve cell viability and achieve functional collaborative therapy between the therapeutics and living cells. Furthermore, the pharmacokinetics of drugs can be improved by leveraging many inherent functions of cells. This review systematically introduces the construction of CDCs as drug delivery systems, including carrier cells, coupling components, and conjugation strategies. The advantages of CDCs as drug delivery systems and the applications of CDCs in the treatment of cancers are highlighted in this paper. Additionally, clinical trials involving CDCs for cancer therapy are analyzed. Finally, the challenges and future directions of CDCs are discussed, with the expectation that their functions will be further explored. It is hoped that this discussion will inspire researchers in their design efforts and ultimately facilitate clinical translation. |  |\n| --- | --- |\n| Keywords: cell-drug conjugates, clinical translation, cancer therapy, precise targeting, drug delivery\u003Cbr>Introduction |  |\n| Cancer remains one of the leading causes of death, imposing a substantial burden on human health [1] . Traditional cancer treatments, including chemotherapy, radiation, surgery, and targeted therapy, have limitations such as non-specific targets, substantial side effects, and the risk of tumor recurrence [2,3] . Nanotechnology has offered promising solutions by improving drug delivery through passive accumulation via the enhanced permeability and retention (EPR) effect. However, nanoparticles (NPs) are rapidly cleared by thereticuloendothelial system (RES), limiting their efficacy [4] . A biofilm-mediated biomimetic nano-drug delivery system (BNDDS) has emerged. This platform uses bio-nanotechnology to encapsulate synthetic NPs within biomimetic membranes, integrating the low immunogenicity, low toxicity, | high tumor targeting, and good biocompatibility of the biofilm with the adjustability and versatility of the nanocarrier, showing promising applications in the field of precision tumor therapy [5,6]. However, being fundamentally NPs, BNDDS cannot overcome the inherent limitations of their structure. A primary challenge is the interfacial energy difference between the biomimetic membrane coating and the synthet","cbCaioydSUW9Ws9J","https://ap.wps.com/l/cbCaioydSUW9Ws9J","pdf",8530532,29,"English","# Abstract\n# Keywords\n# Introduction\n## Limitations of conventional cancer treatments\n## Nanoparticle delivery and the EPR effect\n## Biomimetic nano-drug delivery system limitations\n## Rationale for living-cell delivery and CDC design","[{\"question\":\"What are cell-drug conjugates (CDCs) and how do they achieve targeting?\",\"answer\":\"CDCs are a drug delivery platform that combines living cells with therapeutics. Drugs are conjugated onto cell surfaces so the system leverages cellular biology for more precise targeting while preserving cell viability.\"},{\"question\":\"What challenges limit biomimetic nano-drug delivery systems (BNDDS) in clinical translation?\",\"answer\":\"Because BNDDS are still nanoparticle-based, they face structural and interface-related issues such as weak membrane–core adhesion and rapid clearance. Tumor microenvironment heterogeneity and protein denaturation during preparation can further reduce in vivo effectiveness.\"},{\"question\":\"How does the “living carrier” strategy address limitations of other delivery systems?\",\"answer\":\"CDCs use live cells as delivery vehicles, avoiding certain structural bottlenecks of BNDDS. Therapeutics can be anchored to cell membranes via covalent/non-covalent methods or via genetic engineering, enabling functional integration and collaborative therapy.\"}]","Cell-drug conjugates: a novel drug delivery system for cancer therapy | PDF",1790087262,73,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eca574189a7591ecd14ed4f9b9432964.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb16db3fbf6b6e08b569dc7b1198cfea.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2dfcc04235c298160bd0b2acc4d43c1.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b9caa82fd069373f6f25cf4723c537db.webp",980,1268]